Provides virtual care programs for chronic conditions. Offers clinically validated programs for cardiometabolic disease. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 43% a year over the last 3 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 4.5× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 44% of them.
Analysts' average target sits 32% above today's price.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 43% a year on average.
Sales run at $260.2M a year. A small number, but proof the product has real buyers.
There is $222.0M in the vault; even if every debt were paid off, $222.0M would remain.
A loss of $12.8M against $260.2M in annual sales.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 44/100.
On our five-subject report card, OMDA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OMDA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (44/100) says the stock isn’t cheap.